Cellular Device for the Treatment of Acute Liver Failure

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$499,306.00
Award Year:
2012
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK093285-01A1
Award Id:
n/a
Agency Tracking Number:
R43DK093285
Solicitation Year:
2012
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA11-096
Small Business Information
196 Boston Ave, Medford, MA, 02155
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
828970900
Principal Investigator:
ARNO TILLES
(617) 724-2953
arno.tilles@sentienbiotech.com
Business Contact:
BRIAN MILLER
(781) 361-9031
brian.miller@sentienbiotech.com
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): The goal of this Phase I project is to develop a cell-coated device for the treatment of acute liver failure. The device harnesses mesenchymal stem cell secretions to provide combined anti-inflammatory and regenerativesupport. The project specific aims are: (1) Positron emission tomography (PET)-guided optimization of cellular coatings; and (2) To perform a dose escalation therapeutic trial in an acetaminophen-induced liver failure model in dogs. The deliverable of thiscompleted project will be therapeutic proof-of concept data that can be optimized in large animals during Phase II funding. PUBLIC HEALTH RELEVANCE: Biotechnologies Inc. has developed an extracorporeal device that has the potential to offer unparalleled support to patients undergoing acute liver failure. Th Sentien device delivers to the patient a broad-spectrum array of secreted factors from mesenchymal stem cells. Collectively, these factors protect the injured organ from inflammation and promote endogenous repair programs. This combinatorial approach to liver therapy is distinguishable from the competition and promises to become a disruptive technology. Sentien now seeks funding to finalize its pre-clinical development by creating optimized cellular coatings and performing subsequent in vivo testing in large animal models of liver failure. At the end of these studies, Sentien expects to have sufficient evidence of pre-clinical efficacy to motivate initial trials of this device in humans.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government